CHRISTINA SCHMUTZ: Open Payments
NPI 1962982348 · LONGVIEW, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,566 in 71 payments from 28 companies in 2025. Trend: 2023 $0 · 2024 $341 · 2025 $1,566
Food & beverage: $1,423Education: $93Long term medical supply or device loan: $50
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $201 |
| Lilly USA, LLC | 8 | $167 |
| AstraZeneca Pharmaceuticals LP | 7 | $140 |
| Novartis Pharmaceuticals Corporation | 4 | $104 |
| Abbott Laboratories | 3 | $84 |
| GlaxoSmithKline, LLC. | 5 | $82 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $81 |
| Astellas Pharma US Inc | 1 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $72 |
| Edwards Lifesciences Corporation | 2 | $64 |
Products named: EVENITY, LEQVIO, TRELEGY ELLIPTA, XIFAXAN, AIRSUPRA, UPTRAVI, MOUNJARO, Korlym.
Industry payments across WA — which companies pay providers there.
